LV11326A - Mofetilmikofenolats bezudens kristalu forma - Google Patents

Mofetilmikofenolats bezudens kristalu forma

Info

Publication number
LV11326A
LV11326A LV960085A LV960085A LV11326A LV 11326 A LV11326 A LV 11326A LV 960085 A LV960085 A LV 960085A LV 960085 A LV960085 A LV 960085A LV 11326 A LV11326 A LV 11326A
Authority
LV
Latvia
Prior art keywords
mofetilmcofenolate
crystalline crystal
crystalline
complexing
kit
Prior art date
Application number
LV960085A
Other languages
English (en)
Other versions
LV11326B (en
Inventor
Roger Cherng Fu
De-Mei Leung
Jeffrey S Fleitman
Michele C Rizzolio
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of LV11326A publication Critical patent/LV11326A/lv
Publication of LV11326B publication Critical patent/LV11326B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
LVP-96-85A 1993-09-15 1996-03-15 Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof LV11326B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12184193A 1993-09-15 1993-09-15
PCT/US1994/010142 WO1995007902A1 (en) 1993-09-15 1994-09-12 Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof

Publications (2)

Publication Number Publication Date
LV11326A true LV11326A (lv) 1996-06-20
LV11326B LV11326B (en) 1996-10-20

Family

ID=22399119

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-96-85A LV11326B (en) 1993-09-15 1996-03-15 Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof

Country Status (32)

Country Link
US (2) US5543408A (lv)
EP (1) EP0724581B1 (lv)
JP (1) JP3411038B2 (lv)
KR (1) KR100349772B1 (lv)
CN (1) CN1060770C (lv)
AT (1) ATE173475T1 (lv)
AU (1) AU677435B2 (lv)
BR (1) BR9407469A (lv)
CA (1) CA2171836C (lv)
CZ (1) CZ292423B6 (lv)
DE (1) DE69414720T2 (lv)
DK (1) DK0724581T3 (lv)
ES (1) ES2123831T3 (lv)
FI (1) FI119639B (lv)
HK (1) HK1012624A1 (lv)
HU (1) HU217300B (lv)
IL (1) IL110970A (lv)
LT (1) LT4052B (lv)
LV (1) LV11326B (lv)
MX (1) MXPA94007099A (lv)
NO (1) NO314727B1 (lv)
NZ (1) NZ273801A (lv)
PH (1) PH30685A (lv)
PL (1) PL178522B1 (lv)
RO (2) RO118075B1 (lv)
RU (1) RU2132849C1 (lv)
SG (1) SG55006A1 (lv)
SI (1) SI9420052B (lv)
TW (1) TW370527B (lv)
UA (1) UA49797C2 (lv)
WO (1) WO1995007902A1 (lv)
ZA (1) ZA947088B (lv)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
IN188985B (lv) 1998-12-09 2002-11-30 Biocon Ltd
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
ES2308226T3 (es) * 2003-09-11 2008-12-01 Sandoz Ag Proceso para la produccion de micofenolato mofetil.
US7683188B2 (en) * 2004-04-26 2010-03-23 TEVA Gyógyszergyár Zártkōrūen Mūkōdō Részvénytársaság Process for preparation of mycophenolic acid and ester derivatives thereof
US20050250773A1 (en) * 2004-04-27 2005-11-10 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US7439373B2 (en) * 2004-07-20 2008-10-21 TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság Crystalline mycophenolate sodium
CN100383520C (zh) * 2004-09-20 2008-04-23 复旦大学 一种测定人血浆中霉酚酸及其代谢物的方法
US20060235070A1 (en) * 2005-02-08 2006-10-19 Hayden Michael R Compositions and methods for treating vascular, autoimmune, and inflammatory diseases
WO2006086498A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
US20080281111A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
EP2032521B1 (en) 2006-06-27 2009-10-28 Sandoz AG New method for salt preparation
CN101953807A (zh) * 2010-10-09 2011-01-26 山西普德药业有限公司 一种注射用吗替麦考酚酯冻干粉针剂及其制备方法
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
HUE040044T2 (hu) 2013-03-14 2019-02-28 Alkermes Pharma Ireland Ltd Fumarátok prodrugjai, és azok alkalmazása különbözõ betegségek kezelésében
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
US9604922B2 (en) 2014-02-24 2017-03-28 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US11918684B2 (en) 2017-03-13 2024-03-05 Liqmeds Worldwide Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
CA3212370A1 (en) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328213A (en) * 1979-11-28 1982-05-04 Schering Corporation Stable injectable labetalol formulation
US4478829A (en) * 1983-04-28 1984-10-23 Armour Pharmaceutical Company Pharmaceutical preparation containing purified fibronectin
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions

Also Published As

Publication number Publication date
EP0724581A1 (en) 1996-08-07
JP3411038B2 (ja) 2003-05-26
EP0724581B1 (en) 1998-11-18
LT96028A (en) 1996-08-26
SI9420052A (en) 1996-12-31
PL178522B1 (pl) 2000-05-31
LT4052B (en) 1996-10-25
DE69414720D1 (de) 1998-12-24
UA49797C2 (uk) 2002-10-15
AU677435B2 (en) 1997-04-24
MXPA94007099A (es) 2004-01-23
IL110970A0 (en) 1994-11-28
TW370527B (en) 1999-09-21
LV11326B (en) 1996-10-20
AU7723894A (en) 1995-04-03
DE69414720T2 (de) 1999-04-08
NO961075D0 (no) 1996-03-15
DK0724581T3 (da) 1999-08-02
PL313480A1 (en) 1996-07-08
HU217300B (hu) 1999-12-28
FI961169A (fi) 1996-03-13
ATE173475T1 (de) 1998-12-15
WO1995007902A1 (en) 1995-03-23
FI961169A0 (fi) 1996-03-13
CZ292423B6 (cs) 2003-09-17
NZ273801A (en) 1997-10-24
RU2132849C1 (ru) 1999-07-10
JPH09502721A (ja) 1997-03-18
PH30685A (en) 1997-09-16
NO961075L (no) 1996-03-15
CZ78896A3 (en) 1996-10-16
KR100349772B1 (ko) 2002-12-28
RO118075B1 (ro) 2003-01-30
CA2171836C (en) 2006-11-14
RO118427B1 (ro) 2003-05-30
BR9407469A (pt) 1996-11-12
ES2123831T3 (es) 1999-01-16
HK1012624A1 (en) 1999-08-06
SG55006A1 (en) 1998-12-21
US5545637A (en) 1996-08-13
FI119639B (fi) 2009-01-30
US5543408A (en) 1996-08-06
CN1060770C (zh) 2001-01-17
IL110970A (en) 1999-01-26
SI9420052B (sl) 2004-02-29
HU9600652D0 (en) 1996-05-28
CA2171836A1 (en) 1995-03-23
ZA947088B (en) 1996-03-14
NO314727B1 (no) 2003-05-12
CN1131420A (zh) 1996-09-18
HUT75119A (en) 1997-04-28

Similar Documents

Publication Publication Date Title
LV11326A (lv) Mofetilmikofenolats bezudens kristalu forma
CA2171275A1 (en) Stilbene derivatives and pharmaceutical compositions containing them
MY100359A (en) External pharmaceutical composition.
MX9702380A (es) Nuevas carboxamidas con actividad antifungica.
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
GEP20032953B (en) Antitumor Agents
ATE155469T1 (de) Verfahren zur herstellung von cephemderivaten
TW333532B (en) Benzopyrans
WO1990003172A3 (en) Bile acids for treatment of viral infections
GEP20033054B (en) 2,4,4-Trisubstituted-1,3-Dioxolane Antifungals
ES8202561A1 (es) Un procedimiento para la produccion de 11,12-carbonato de eritromicilamina
IT1195852B (it) Impiego di l-carnitina nel trattamento degli effetti tossici indotti dall'inalazione di alotano e di altri anestitici generali alogenati
GT199300039A (es) Sales de cefalosporina y procedimiento para su preparacion
FI890954A (fi) Anordning foer begraensning av den magnetiska straolningen i katodstraoleroermonitorer.